Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Aptamer Group Plc ( (GB:APTA) ) has provided an update.
Aptamer Group has signed a non-exclusive worldwide OEM licensing agreement with Alphazyme, a Maravai LifeSciences company, for an enzyme‑modulating Optimer® used in hot‑start PCR and next-generation sequencing applications. The deal, which follows a successful development programme completed in late 2024, includes royalties on Alphazyme’s product sales, milestone payments, and a supply agreement under which Aptamer will manufacture the Optimer®, creating additional revenue streams and supply-chain leverage. The Optimer® binder enables temperature‑sensitive control of key enzyme activities and can replace two traditional antibodies with a single molecule, offering performance and cost advantages; this second enzyme‑modulation licence with Alphazyme is presented by Aptamer as a commercial and technical validation of its Optimer® platform and is expected to support further licensing opportunities and expansion of both companies’ product portfolios.
The most recent analyst rating on (GB:APTA) stock is a Hold with a £0.77 price target. To see the full list of analyst forecasts on Aptamer Group Plc stock, see the GB:APTA Stock Forecast page.
Spark’s Take on GB:APTA Stock
According to Spark, TipRanks’ AI Analyst, GB:APTA is a Neutral.
Aptamer Group Plc’s overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and negative cash flows. The technical analysis suggests a bearish trend, and the valuation is unattractive due to a negative P/E ratio and no dividend yield. These factors collectively contribute to a low overall stock score.
To see Spark’s full report on GB:APTA stock, click here.
More about Aptamer Group Plc
Aptamer Group plc, listed on AIM, develops next‑generation synthetic binders called Optimer® for the life sciences industry, targeting applications in molecular biology, diagnostics, and next-generation sequencing. Its technology is positioned as an alternative to antibodies, aiming to deliver enhanced performance and cost efficiencies for partners and customers in global research and diagnostic markets.
Average Trading Volume: 8,843,445
Technical Sentiment Signal: Hold
Current Market Cap: £20.23M
See more data about APTA stock on TipRanks’ Stock Analysis page.